Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Cell Therapeutics, Inc. (NasdaqNM:CTIC)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
July 26Conference call: Cell Therapeutics Earnings (Q2 2001)
Location
201 Elliot Avenue West, Suite 400
Seattle, WA 98119
Phone: (206) 282-7100
Fax: (206) 284-6206
Email: invest@ctiseattle.com
Employees (last reported count): 147
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 37%
·Over the last 6 months:
 · 3 insider sells; 666.0K shares
  (5.1% of insider shares)
·Institutional: 71% (114% of float)
(229 institutions)
·Net Inst. Buying: 2.39M shares (+9.01%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Cell Therapeutics, Inc. acquires and commercializes novel treatments for cancer. The Company's goal is to build a leading, vertically integrated biopharmaceutical company with a diversified portfolio of proprietary oncology drugs. The Company's research and in-licensing activities are concentrated on identifying new, less toxic and more effective ways to treat cancer. The Company's lead product, called arsenic trioxide, or TRISENOX, received FDA approval in September 2000. TRISENOX is initially being marketed for patients with a type of blood cell cancer called Acute Promyelocytic Leukemia (APL), who have relapsed or failed available therapies. In its pivotal trial in patients with relapsed or refractory APL, 70% of the 40 patients experienced complete remission following treatment with TRISENOX, with 78% entering a molecular remission.
More from Market Guide: Expanded Business Description

Financial Summary
Cell Therapeutics is a biopharmaceutical company committed to making cancer a treatable disease by discovering, developing and bringing to market innovative treatments for cancer. For the six months ended 6/30/01, revenue totaled $2.8 million, vs. $0. Net loss applicable to Common rose 20% to $27.7 million. Results reflect initial product sales for Trisenox, offset by higher amortization costs due to the acquisition of PolaRx, and marketing expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Max Link, Ph.D., 60
Chairman of Directors, Director
--  --  
James Bianco, M.D., 44
Pres, CEO, Director
$742K$6.6M
Louis Bianco, 48
Exec. VP, Fin. and Admin.
365K107K
Edward Kenney, 56
Exec. VP, COO
225K--  
Jack Singer, M.D., 58
Exec. VP, Research Program Chairman
271K1.2M
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:CTICAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Mar-2001
$12.50 
Recent Price$30.32 
52-Week High
on 20-Oct-2000
$77.25 
Beta1.01 
Daily Volume (3-month avg)566.2K
Daily Volume (10-day avg)441.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-35.9%
52-Week Change
relative to S&P500
-14.0%
Share-Related Items
Market Capitalization$1.02B
Shares Outstanding33.7M
Float21.2M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$4.46 
Earnings (ttm)-$1.85 
Earnings (mrq)-$0.47 
Sales (ttm)$0.11 
Cash (mrq)$8.16 
Valuation Ratios
Price/Book (mrq)6.80 
Price/EarningsN/A 
Price/Sales (ttm)285.27 
Income Statements
Sales (ttm)$3.32M
EBITDA (ttm)-$54.0M
Income available to common (ttm)-$57.0M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-29.55%
Return on Equity (ttm)-38.89%
Financial Strength
Current Ratio (mrq)24.99 
Debt/Equity (mrq)1.00 
Total Cash (mrq)$274.9M
Short Interest
As of 8-Aug-2001
Shares Short3.76M
Percent of Float17.7%
Shares Short
(Prior Month)
2.83M
Short Ratio5.55 
Daily Volume677.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.